Decreased expression of Sema3A, an immune modulator, in blood sample of multiple sclerosis patients

Publication date: 30 April 2017
Source:Gene, Volume 610
Author(s): Mahsa Rezaeepoor, Shima Shapoori, Mazdak Ganjalikhani-hakemi, Masoud Etemadifar, Fereshteh Alsahebfosoul, Nahid Eskandari, Marjan Mansourian
Semaphorin 3A (Sema3A) as an immune modulator could participate in the pathogenesis of autoimmune diseases. In the current study, we aimed to investigate Sema3A expression in peripheral blood mononuclear cells (PBMCs) and its serum level in relapsing-remitting multiple sclerosis (RRMS) patients. Fifteen newly determined and untreated RRMS patients were chosen and assessed in relapsing and remitting phases in compare with fifteen healthy individuals. In consistent with previous findings in other autoimmune diseases, our results revealed that serum level of Sema3A and its expression in PBMCs of RRMS patients were significantly lower than in normal subjects. We also evaluated this down regulation predictive value with ROC analysis. According to our data, we suggest that Sema3A could be involved in pathogenesis of MS and might be a potential diagnostic biomarker for the disease.

Graphical abstract

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lMmtzX
via IFTTT